Conseil pour considération du vaccin conjugué quadrivalent contre le méningocoque (A, C, Y, W135) pour utilisation par les provinces et territoires

Références

• ACIP (2005). Prevention and control of meningococcal disease. Recommandations du Advisory Committee on Immunization Practices. MMWR 54 (RR-7) : 1-21.
• Agence de la santé publique du Canada (ASPC) (2007). Programmes d'immunisation subventionnés par l'État au Canada - Calendrier d'immunisation systématique des nourrissons et des enfants (incluant les programmes de rappel).
• Alonso JM et coll. (2007). Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 mars 2005. Vaccine 25 : 4125-9.
• Andrews N, Borrow R, Miller E (2003). Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10 : 780-786.
• Ashton FE, Caugant DA (2001). The panmictic nature of Neisseria meningitidis serogroup B during a period of endemic disease in Canada. Can J Microbiol 47 : 283-89.
• Auckland C, Gray S, Borrow R et coll. (2006). Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. JID 194: 1745 – 52.
• Borrow R, Balmer P, Miller E (2005). Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23 : 2222-7.
• Caro JJ, Möller J, Getsios D et coll. (2007). Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health 7 : 130.
• Cartwright K (1995). Meningococcal carriage and disease. In. Meningococcal disease. Ed.
• Cartwright K. Chichester, U.K. : John Wiley & Sons : 71-114.
• CDC (2006). Notice to readers : Improved supply of meningococcal conjugate vaccine, recommendation to resume vaccination of children aged 11-12 years. MMWR 55 (43) : 1177.
• Comité consultatif national de l'immunisation (CCNI) (2005). Le point sur les vaccins conjugués contre le méningocoque. RMTC vol. 31 (DCC-3) : 1-4.
• Comité consultatif national de l'immunisation (CCNI) (2007). Déclaration sur le vaccin conjugué contre le méningocoque, sérogroupes A, C, Y et W135. RMTC vol 33 (DCC-3): 1-24.
• Committee on Safety of Medicines Expert Working Group. (2002). Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines. London, UK, Department of Health.
• De Wals P (2000). L'information sur le risque de contracter le syndrome de Guillain-Barré peut- elle modifier l'intention de se faire vacciner contre l'influenza? RMTC 26 : 205-7.
• De Wals P (2006). Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 5 : 269-75.
• De Wals P, Allard MA, Guindon K et coll. (2002). La vaccination contre le méningocoque est-elle utile? Résultats d'une enquête dans la région de Sherbrooke (Québec) RMTC Vol. 28 : 61-63.
• De Wals P, Coudeville L, Trottier P et coll. (2007). Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 25 : 5433-40.
• De Wals P, Deceuninck G, Boulianne N et coll. (2004). Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 292 : 2491-2494.
• De Wals P, Deceuninck G, De Serres G et coll. (2005). Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis 40 1116-22.
• De Wals P, Duval B, De Serres G et coll. (2003). Santé publique : le contrôle des maladies méningococciques au Québec. Médecine/Sciences 19 : 1011-5.
• De Wals P, Nguyen VH, Erickson LJ et coll. (2004). Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 22 : 1233-40.
• De Wals P, Trottier P, Pépin J (2006). Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24 3500- 4.
• Deeks S, Kertesz D, Ryan A et coll. (1997). Surveillance de la méningococcie invasive au Canada, 1995-1996. RMTC vol. 23-16 :121-125.
• El Bashir H, Heath PT, Papa T et coll. (2006). Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine 24 : 2544-2549.
• Erickson L, De Wals P (1998). Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 26:1159-64.
• Erickson LJ, De Wals P, Farand L (2005). An analytical framework for immunization program planning in Canada. Vaccine 23 : 2468-74.
• Frasch CE (1995). Meningococcal vaccines: past, present and future. Dans : Cartwright K, ed. Meningococcal disease. Chichester: John Wiley and Sons : 245-83.
• Girard MP, Preziozi MP, Aguado MT et coll. (2006). A review of vaccine research and development: Meningococcal disease. Vaccine 24 : 4692-4700.
• Goldschneider I, Gotschlich EC, Artenstein MS (1969). Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 : 1307-26.
• Granoff DM, Harris SL (2004). Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 23 : 490-7.
• Granoff DM, Morgan A, Welsch JA (2005). Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. Vaccine 23 : 4307-4314.
• Granoff DM, Morgan A, Welsch JA (2005). Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis- diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 24 : 132-36.
• Guay M, Clouâtre AM, Blackburn M et coll. (2003). Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren. Can J Public Health 94 : 64-7.
• Haber P, DeStefano F, Angulo FJ et al (2004). Guillain-Barré syndrome following influenza vaccination. JAMA 292 : 2478-81.
• Hahn A (1998). Guillain-Barré syndrome. Lancet 352 : 635-41.
• Harrison LH, Jolley KA, Shutt KA et coll. (2006). Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 193 : 1266-74.
• Hughes RA, Charlton J, Latinovic R et coll. (2006). No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 166 : 1301-4.
• Hughes RA, Cornblath DR (2005). Guillain-Barré syndrome. Lancet 366 : 1653-66.
• Hurwitz ES, Schonberger LB, Nelson DB et coll. (1981). Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 304 : 1557-61.
• Kaplan JE, Katona P, Hurwitz ES et coll. (1982). Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 248 : 698-700.
• Lagos R, Papa T, Munoz A et coll. (2005). Safety and immunogenicity of a meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile. Human Vaccines 1 : 228-31.
• Langmuir AD, Bregman DJ, Kurland LT et coll. (1984). An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 119 : 841-79.
• Larrauri A, Cano R, Garcia M et coll. (2005). Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23 : 4097-100.
• Lasky T, Terracciano GJ, Magder L et coll. (1998). The Guillain-barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 339 : 1797-1802.
• Law DKS, Stoltz J, Henderson AM et al (2005). Antigenic and genetic characterization of serogroup C meningococci isolated from invasive meningococcal disease in Canada from 1999 to 2003. Can J Microbiol 51 : 523-30.
• Lorange M, Jetté L (2002). Surveillance des infections envahissantes à Neisseria meningitidis. Rapport annuel 2001. Québec : Institut national de santé publique, Laboratoire de santé publique du Québec.
• Maiden MC, Stuart JM for The U.K. Meningococcal Carriage Group (2002). Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 : 1829-30.
• MSSS (Ministère de la Santé et des Services sociaux) (2004). Protocole d'immunisation du Québec. Québec (QC) : Ministère de la Santé et des Services sociaux.
• Orenstein WA, Bernier R, Hinman AR (1988). Assessing vaccine efficacy in the field. Epidemiol Rev 10: 212-241.
• Pichichero M, Casey J, Blatter M et coll. (2005). Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two-to ten-year-old children. Pediatr Infect Dis J 24 : 57-62.
• Pichichero ME (2005). Meningococcal conjugate vaccines. Expert Opin Biol Ther 5 : 1475-89.
• Pollard AJ (2004). Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 23 (supplement) : S274-9.
• Pollard AJ, Frasch C (2001). Development of natural immunity to Neisseria meningitidis. Vaccine 19 : 1327-46.
• Ramsay ME, Andrews NJ, Trotter CL et coll. (2003). Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326 : 365-6.
• Rennels M, King J, Ryall R et al (2002). Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 21 : 978-979.
• Rennels M, King Jr. J, Ryall R et coll. (2004). Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 23 : 429-35.
• Richmond P, Borrow R, Goldblatt D et al (2001). Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 183 : 160 -3.
• Rivest P, Sagot B, Bédard L (1999). Evaluation of the completeness of reporting of invasive meningococcal disease. Can J Public Health 90 : 250-251.
• Roscelli JD, Bass JW, Pang L (1991). Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. Am J Epidemiol 133 : 952-5.
• Rosenstein NE, Perkins BA, Stephens DS et coll. (2001). Meningococcal disease. N Engl J Med 344 : 1378-88.
• Sanofi Pasteur Limited (2006). Product monograph. Menactra™. Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine. Toronto, Ontario.
• Santé Canada (1997). Rapport sur l'immunisation au Canada, 1996, RMTC vol 23-S4.
• Slovic P (1987). Perception of risk. Science 236 : 280-5.
• Snape MD, Kelly DF, Salt P et coll. (2006). Serogroup C meningococcal glycoconjugate vaccine in adolescents: Persistance of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. CID 43: 1387-94.
• Squires SG, Deeks SL (2004). Surveillance accrue des méningococcies invasives au Canada : du 1^er janvier 1999 au 31 décembre 2001. RMTC vol. 30 :17-28.
• Squires SG, Pelletier L, Mungai M et coll. (2000). Les méningococcies invasives au Canada, du 1^er janvier 1997 au 31 décembre 1998. RMTC vol. 26-21 : 177-182.
• Statistique Canada (1996). Life tables, Canada and Provinces 1990-1992. Catalogue 84-537 Occasional. Ottawa.
• Stein KE (1992). Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 165 (Suppl. 1) : S49-52.
• Stephens DS, Greenwood B, Brandtzaeg P (2007). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369 : 2196-210.
• Stratton K, Alamario DA, Wizemann T et coll. (2004). Immunization safety review : Influenza vaccines and neurological complications. Washington, DC : Institute of Medicine.
• Trotter CL, Andrews NJ, Kaczmarski EB et coll. (2004). Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364 : 365-67.
• Trotter CL, Edmunds WJ (2002). Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 324 : 1-6.
• Trotter CL, Gay NJ, Edmunds WJ (2005). Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 162 : 89-100.
• Tsang RS, Henderson AM, Cameron ML et coll. (2007). Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 45 : 1753-8.
• Vu DM, Welsch JA, Zuno-Mitchell P et coll. (2006). Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 193 : 821-8.
• Welsh JA, Granoff D (2004). Naturally acquired passive protective activity against Neisseria meningitidis group C in the absence of serum bactericidal activity. Infect. Immun. 72 : 5903-9.
• Woo EJ, Ball R, Braun M et coll. (2006). Update : Guillain-Barré syndrome among recipients of Menactra™ meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR 55 (41) : 1120-4.
• Zhang Q, Choo S, Everard J et coll. (2000). Mucosal immune responses to meningococcal Group C conjugate and Group A and C polysaccharide vaccines in adolescents. Infect Immun 68 : 2692-7.
• Zhang Q, Pettitt E, Burkinshaw R et coll. (2002). Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J 21 : 209-13.

[Précédent] [Table des matières]